Business
Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that data from its 28-day multiple ascending dose study of its oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 (NCT06680440) will be presented in a short oral discussion at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting held in Vienna, Austria.
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":" - Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion ","length":104,"tagName":"p"},{"type":"text","content":" - On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the fourth quarter of 2025 ","length":157,"tagName":"p"},{"type":"text","content":"HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that data from its 28-day multiple ascending dose study of its oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 (NCT06680440) will be presented in a short oral discussion at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting held in Vienna, Austria.","length":397,"tagName":"p"},{"type":"text","content":" Details of the Short Oral Discussion ","length":36,"tagName":"p"},{"type":"text","content":" Abstract Title: ASC30, an oral GLP-1R biased small molecule agonist demonstrated superior weight loss in participants with obesity: a 28-day multiple ascending dose study","length":171,"tagName":"p"},{"type":"text","content":" Short Oral Discussion Sessions Event A: SO 073 The GLP-1 portfolio: diverse formulations for expanding clinical applications","length":125,"tagName":"p"},{"type":"text","content":" Presentation Time: September 16, 2025, 12:00 - 13:00 CEST","length":58,"tagName":"p"},{"type":"text","content":" Presentation Number: 827","length":25,"tagName":"p"},{"type":"text","content":""We look forward to presenting our ASC30 oral tablet clinical data to the community at this year's EASD Annual Meeting," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. "We believe that these efficacy and safety data will position ASC30 oral tablet as a potentially differentiated option for the treatment of obesity."","length":361,"tagName":"p"},{"type":"text","content":" About ASC30 ","length":11,"tagName":"p"},{"type":"text","content":"ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044 without patent extensions.","length":334,"tagName":"p...